Triple incretin agonists activate three metabolic hormone receptors:
These agents are investigational and represent the next evolution in incretin-based metabolic therapy.
→ Dual GLP-1/GIP Incretin Agonists → GLP-1 Receptor Agonists
Each receptor contributes unique metabolic effects.
GLP-1 receptor activation:
GIP receptor activation:
Glucagon receptor activation:
The combination aims to:
Triple agonists:
Hypoglycemia risk remains low due to glucose-dependent insulin release.
Retatrutide is the most advanced triple incretin agonist in clinical development.
Early trials show:
Not yet FDA approved.
Compared to:
Triple agonists may produce:
Long-term cardiovascular outcome data are pending.
Similar expected adverse effects to GLP-1 agents:
Potential concerns:
Long-term safety is still under investigation.
Triple incretin therapy may redefine obesity and diabetes management.
Ongoing studies are evaluating:
These agents represent a shift toward multi-hormonal metabolic modulation.